ARTICLE | Company News
Allergan pharmaceuticals news
February 9, 2009 8:00 AM UTC
Allergan reduced headcount by 460 (5%) mostly in sales and marketing. The company will seek a partner to promote overactive bladder drug Sanctura XR to general practitioners. Allergan already co-promotes Sanctura XR in the urology specialty area in North America with Indevus Pharmaceuticals Inc. (NASDAQ:IDEV, Lexington, Mass.). Sanctura trospium, a muscarinic receptor antagonist, and Sanctura XR, a once-daily formulation of trospium chloride, posted 2008 sales of $70 million. ...